UroGen Pharma Ltd.URGN
What UroGen Pharma Ltd. does.
We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs. Our technology is designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our approved products Jelmyto (mitomycin) for pyelocalyceal solution and Zusduri (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer (“low-grade UTUC”) and recurrent low-grade intermediate risk non-muscle invasive bladder cancer (“low-grade intermediate risk NMIBC”), respectively. In addition, our immuno-uro-oncology pipeline includes UGN-501 (formerly known as ICVB-1042), a next-generation investigational oncolytic virus.
RTGel is a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology, which, unlike the general characteristics of most forms of matter, is liquid at lower temperatures and converts into gel form when warmed to body temperature. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urinary tract, forming a transient reservoir of drug that dissolves over time while preventing rapid excretion and providing for increased dwell time. RTGel leverages the physiologic flow of urine to provide a natural exit from the body.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | $109.8M |
| Net income | -$128.5M | -$110.8M | -$109.8M | -$102.2M | -$126.9M | -$153.5M |
| Free cash flow | -$107.1M | -$85.6M | -$87.8M | -$76.6M | -$97.1M | -$162.7M |
More on URGN.
- UroGen Pharma Ltd. summary
- UroGen Pharma Ltd. financial statements
- UroGen Pharma Ltd. key metrics
- UroGen Pharma Ltd. health scores and style box
- UroGen Pharma Ltd. earnings
- UroGen Pharma Ltd. dividends
- UroGen Pharma Ltd. valuation
- UroGen Pharma Ltd. ownership and insiders
- UroGen Pharma Ltd. peers
Figures from UroGen Pharma Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.